As of January 1, 2024, Klaus Seliger has joined the Advisory Board of Hevert-Arzneimittel. The management consultant brings his extensive experience in the pharmaceutical industry to the board. Long-time member Frank D. Kube departs the Advisory Board after 14 years.
For over twenty years, the Advisory Board of Hevert-Arzneimittel has been advising Hevert shareholders Sarah Hevert-Ernst, Marcus, and Mathias Hevert in legal, marketing, sales, and financial matters. This year, Klaus Seliger from Bingen has joined the board as a new member.
New advisory board member with solid expertise in pharmaceutical OTC marketing
At the first Advisory Board meeting of the year, the Hevert shareholders and the Advisory Board members Franz-Josef Hans and Dr. Axel Sander welcomed the new member Klaus Seliger. Seliger primarily contributes his solid expertise in the marketing of consumer healthcare products (OTC) to the board.
With roles at companies such as Boehringer Ingelheim, Merck, Almirall, Taurus Pharma, and Luvos, Seliger has over forty years of experience both in pharmaceutical corporate settings and in medium-sized businesses. During this time, he has successfully developed and managed OTC brands in Germany and internationally, specializing in strategic marketing and the operational implementation of strategies. The well-connected marketing expert from Bingen now works as an independent management consultant.
Klaus Seliger succeeds Frank D. Kube, who stepped down from his advisory role on December 31, 2023. Business graduate Frank D. Kube had been a member of the Advisory Board since 2009. Prior to his advisory role, he managed the German and Swiss OTC business of Wyeth and was the managing director of Whitehall-Much GmbH. The Hevert-Arzneimittel Advisory Board not only relied on Kube’s OTC expertise but also valued his knowledge from his role as chair of the Committee for Communication and Public Relations of the German Association of Pharmaceutical Manufacturers (BAH) e.V., and his position on the BAH board.
“We sincerely thank Mr. Kube for his long-standing and trustworthy collaboration,” appreciates Mathias Hevert, Managing Director of Hevert-Arzneimittel, Kube’s service to the board. “We will greatly miss his competent support. At the same time, we are pleased to have found in Mr. Seliger an equally experienced successor. The advisory support of the Hevert-Arzneimittel Advisory Board plays a significant role in the strategic orientation of our family business towards becoming an innovative and agile naturopathic company that combines sustainable health for people with ecological sustainability for the environment.”
Frank D. Kube was officially bid farewell at a meeting at the beginning of the year by the Hevert shareholders and advisory board members.
